Research programme: RNAi therapeutics - Arbutus

Drug Profile

Research programme: RNAi therapeutics - Arbutus

Alternative Names: LNP-siRNA therapeutics - Arbutus; TKM-ALDH; TKM-GSD; TKM-HTG; TKM-Marburg; WEE1/CSN5

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protiva Biotherapeutics
  • Developer Arbutus Biopharma
  • Class Gene therapies; Small interfering RNA
  • Mechanism of Action COPS5 protein inhibitors; RNA interference; WEE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alcoholism; Marburg virus disease; Metabolic disorders

Highest Development Phases

  • Suspended Alcoholism; Hypertriglyceridaemia; Marburg virus disease; Non-alcoholic steatohepatitis; Solid tumours
  • No development reported Lysosomal storage diseases

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Lysosomal storage diseases in USA (Parenteral)
  • 21 Mar 2017 Suspended - Preclinical for Alcoholism (TKM ALDH) in USA (Parenteral) (Arbutus 10-K 2017)
  • 21 Mar 2017 Suspended - Preclinical for Hypertriglyceridaemia (TKM HTG) in USA (Parenteral) (Arbutus 10-K 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top